Evolut PRO+ System (chronic dialysis patients) Use-Results Surveillance
Not Applicable
Recruiting
- Conditions
- aortic stenosis
- Registration Number
- JPRN-UMIN000051216
- Lead Sponsor
- Medtronic Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
N/A
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are implicated in aortic stenosis progression among chronic dialysis patients using Evolut PRO+ System?
How does Evolut PRO+ System TAVR compare to surgical aortic valve replacement in dialysis patients with severe aortic stenosis?
Which biomarkers correlate with improved outcomes in chronic dialysis patients undergoing transcatheter aortic valve replacement with Evolut PRO+?
What are the unique adverse event profiles and management strategies for Evolut PRO+ System in end-stage renal disease patients with aortic stenosis?
How do Medtronic's Evolut PRO+ System results in dialysis patients align with competitor TAVR devices like Edwards Sapien 3 in aortic stenosis treatment?